Table 3.

Results of meta-analysis of histologic subtypes of MMR deficient ovarian cancers

	HNPCC-associated ovarian cancers	MSI-H ovarian cancers	Ovarian cancers with loss of MMR expression	Pooled analysis of all 3 categories
	Proportion (95% CI)	Proportion (95% CI)	Proportion (95% CI)	Proportion (95% CI)
Serous	0.42 (0.29–0.55)	0.36 (0.18–0.57)	0 (0)	0.32 (0.20–0.44)
Nonserous	0.57 (0.44–0.70)	0.063 (0.42–0.81)	0.95 (0.81–0.99)	0.68 (0.56–0.80)
Mucinous	0.16 (0.08–0.25)	0.22 (0.07–0.42)	0.26 (0.05–0.55)	0.19 (0.12–0.27)
Endometrioid	0.25 (0.17–0.35)	0.32 (0.21–0.45)	0.34 (0.10–0.64)	0.29 (0.22–0.36)
Clear cell	0.17 (0.07–0.30)	0.10 (0.009–0.27)	0.35 (0.15–0.58)	0.18 (0.09–0.28)
Undifferentiated	1 study	—	—	1 study
Mixed	1 study	1 study	1 study	0.24 (0.07–0.47)

NOTE: The table includes MMR-deficient ovarian cancers identified based on (a) positive family history and/or germline mutation analysis, (b) MSI-H status and/or (c) lack of MMR protein expression, stratified by each category, as well as the pooled analysis.